Pune, India, June 03, 2021 (GLOBE NEWSWIRE) -- The increasing prevalence of rare cancer is driving the global “hairy cell leukemia therapeutics market”, says Fortune Business Insights in a report, titled “Hairy Cell Leukemia Therapeutics Market Size, Share and Global Trend by Treatment (Chemotherapy, Biological Therapy, Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Geography Forecast till 2026.” Rising demand for the prevention of second cancer is fostering the growth of the global hairy cell leukemia therapeutics market.
Request a Sample Copy of the Research Report
FDA’s Approved Lumoxiti to Support Growth
MedImmune, a subsidiary of AstraZeneca for biologics research and development received approval from the Food and Drug Administration for Lumoxiti. Lumoxiti will be used for the treatment of relapsed or refractory hairy cell leukemia (HCL) in adult patients. The launch of Lumoxiti is expected to support the growth of the hairy cell leukemia therapeutics drugs owing to the overall response of the treatment.
Further, the acquisitions between Innate Pharma and AstraZeneca are also contributing to the hairy cell leukemia therapeutics revenue. For instance, Innate Pharma entered into a multi-term agreement with AstraZeneca which resulted in the acquisition of commercialization rights of Lumoxiti in the U.S. and Europe. The commercialization of Luxomiti on a global scale will further boost the global hairy cell leukemia therapeutics market.
Please Visit:
https://www.fortunebusinessinsights.com/industry-reports/hairy-cell-leukemia-therapeutics-market-100616
Increasing Cases of Rare Cancer Around the World to Promote Growth
The increasing cases of rare cancer and growing geriatric population are expected to contribute to hairy cell leukemia therapeutics market growth. Rising awareness regarding hairy cell leukemia therapeutics prognosis and efficient diagnosis is also supporting the growth of the hairy cell leukemia therapeutics market.
The rising cases of cancer amongst rural population exposed to toxins through fertilizers and the increasing demand for the prevention of second cancers are factors driving the global hairy cell leukemia therapeutics market. In a report American Cancer Society estimates patients diagnosed with Hairy Cell Leukemia are given therapeutics through chemotherapy, they give a good response that often lasts more than five years.
According to Cancer Research UK, an estimation of 90 out of 100 patients (90%), survive their leukemia for more than five years after successful treatment and move towards remission. Often when leukemia returns, the same course of treatment is administered, and if not successful, alternatives such as biological therapies are administered. This trend, combined with the other factors are expected to contribute positively to the hairy cell leukemia therapeutics revenue.
Quick Buy Hairy Cell Leukemia Therapeutics Market
https://www.fortunebusinessinsights.com/checkout-page/100616
Increasing R&D Investments will Facilitate Growth in the U.S.
Geographically the global hairy cell leukemia therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America leads the global market and is predicted to dominate in the forthcoming year due to the increasing R&D investments and the presence of advanced diagnostics.
Advancements in the treatment of hairy cell leukemia and product launches by key players is propelling growth in the region. In 2018, AstraZeneca received FDA approval for Lumoxiti, intravenous injection for hairy cell leukemia, which is expected to speed up the growth of the global hairy cell leukemia market in North America. Asia Pacific is expected to grow as an emerging market owing to increasing cases of cancer and developing healthcare infrastructure. The increasing awareness about early diagnosis and the adoption of advanced medical therapeutics is also fostering growth in the region.
Get your Customized Research Report:
Some of the major companies that are present in the global hairy cell leukemia therapeutics market are
- AstraZeneca
- AbbVie Inc.
- Biogenomics Limited.
- F. Hoffmann-La Roche Ltd
- Astellas Pharma Inc.
- Janssen Pharmaceuticals, Inc.
- Juno Therapeutics.
Have Any Query? Ask Our Experts
Segmentation of the Global Hairy Cell Leukemia Therapeutics Market
- By Treatment
- Chemotherapy
- Biological Therapy
- Others
- By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- By Geography
- North America (USA and Canada)
- Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)
- Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
- Latin America (Brazil, Mexico and Rest of Latin America)
- Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Have a Look at Related Reports:
Urinary Incontinence Devices Market Size, Share and Global Trend By Product (Urethral Inserts, Pessary, Male Slings, Female Slings, Artificial Urinary Sphincters, Electrical Stimulation Devices), By Type (Stress Incontinence, Urge Incontinence, Overflow Incontinence, Mixed Incontinence), By Patient (Male & Female), By End User (Clinics, Hospitals, Ambulatory Surgery Centres, Home Care Settings) and Geography Forecast till 2021-2028
Veterinary Point-of-Care Diagnostics Market Size, Share and Global Trend By Types (kit, Instruments), Application (Hormone Level Testing, Infectious Disease Testing), End Users (Veterinary Hospitals, Home Care Settings, Veterinary Clinics) and Geography Forecast till 2021-2028
Disposable Contact Lenses Market Size, Share and Global Trend by Type (Cylindrical Lenses, Toric Lenses, Spherical Lenses), By Distribution Channel (Optical Stores, Online Stores), By Material (Silicon, Hydrogel, Polymers, Hydrogel), By Usage (Corrective Lenses, Therapeutic Lenses, Cosmetic) and Geography Forecast till 2021-2028
Eye Supplements Market Size, Share and Global Trend By Product Type (Antioxidants, Fatty Acids, Anti-inflammatory Supplements, Neuro-protective supplements), By Form (Liquid, Gels, Capsule, Tablet), By Application(Eye Health, Muscular Degeneration, Diabetic Retinopathy, Cataract, Glaucoma), By Distribution Channels(Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)and Geography Forecast till 2021-2028
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:
Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.
Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email:sales@fortunebusinessinsights.com